1353891-88-9

Basic information

• Product Name: tert-butyl ((1R,2S)-2-amino-1,2-bis(4-chlorophenyl)ethyl)carbamate
• Synonyms: tert-butyl ((1R,2S)-2-amino-1,2-bis(4-chlorophenyl)ethyl)carbamate
• CAS NO: 1353891-88-9
• Molecular Weight: 381.302
• Mol File: 1353891-88-9.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: tert-butyl ((1R,2S)-2-amino-1,2-bis(4-chlorophenyl)ethyl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl ((1R,2S)-2-amino-1,2-bis(4-chlorophenyl)ethyl)carbamate(1353891-88-9)
• EPA Substance Registry System: tert-butyl ((1R,2S)-2-amino-1,2-bis(4-chlorophenyl)ethyl)carbamate(1353891-88-9)

Safety Data

• Hazardous Substances Data: 1353891-88-9(Hazardous Substances Data)

Upstream product

• 86212-34-2 (1R,2S)-1,2-bis(4-chlorophenyl)ethane-1,2-diamine 
• 3848-36-0 4-chlorobenzaldoxime 
• 774225-25-1 N-(tert-butoxycarbonyl)-α-(phenylsulfonyl)-4-chlorobenzylamine 
• 4248-19-5 tert-butyl carbazate 
• 104-88-1 4-chlorobenzaldehyde 
• 106-43-4 para-chlorotoluene 
• 1353891-52-7 tert-butyl ((1R,2S)-1,2-bis(4-chlorophenyl)-2-nitroethyl)carbamate 
• 779342-75-5 tert-butyl 4-chlorobenzylidenecarbamate 
• 29559-24-8 4-chlorophenylnitromethane 
• 622-95-7 4-chlorobenzyl bromide 

Downstream Products

• 548472-68-0 nutlin-3a 
• 1353891-92-5 N-((1S,2R)-2-amino-1,2-bis(4-chlorophenyl)ethyl)-2-isopropoxy-4-methoxybenzamide 
• 1353891-93-6 N-((1R,2S)-1,2-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxybenzamido)ethyl)-3-oxopiperazine-1-carboxamide 
• 1353891-90-3 tert-butyl (1R,2S)-1,2-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxybenzamido)ethylcarbamate 

Relevant articles and documents

Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor

The aberrant interaction between p53 and Mdm2/MdmX is an attractive target for cancer drug discovery because the overexpression of Mdm2 and/or MdmX ultimately impairs the function of p53 in approximately half of all human cancers. Recent studies have show

Chiral synthesis method for producing cis-imidazoline compounds for pharmaceutical use

This invention provides a method for enantioselective synthesis of cis-imidazolines and related structures through chiral resolution. A chiral acid is used to separate enantiomeric precursors of the cis-imidazolines from a racemic mixture by selective cry

Preparation of (-)-nutlin-3 using enantioselective organocatalysis at decagram scale

Chiral nonracemic cis-4,5-bis(aryl)imidazolines have emerged as a powerful platform for the development of cancer chemotherapeutics, stimulated by the Hoffmann-La Roche discovery that Nutlin-3 can restore apoptosis in cells with wild-type p53. The lack of efficient methods for the enantioselective synthesis of cis-imidazolines, however, has limited their more general use. Our disclosure of the first enantioselective synthesis of (-)-Nutlin-3 provided a basis to prepare larger amounts of this tool used widely in cancer biology. Key to the decagram-scale synthesis described here was the discovery of a novel bis(amidine) organocatalyst that provides high enantioselectivity at warmer reaction temperature (-20 C) and low catalyst loadings. Further refinements to the procedure led to the synthesis of (-)-Nutlin-3 in a 17 g batch and elimination of all but three chromatographic purifications.